

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
Alexandria, Virginia 22313-1450

P .	_				
APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/700,770	(	01/16/2001	Fei Yang	DEX-0113	8352
26259	7590	10/21/2003		EXAMINER	
LICATLA & TYRRELL P.C. 66 E. MAIN STREET				YAEN, CHRISTOPHER H	
MARLTON, NJ 08053				ART UNIT	PAPER NUMBER
				1642	***

DATE MAILED: 10/21/2003

20

Please find below and/or attached an Office communication concerning this application or proceeding.

<del>,</del>		Application No.	Applicant(s)				
		09/700,770	YANG ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Christopher H Yaen	1642				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1)⊠	Responsive to communication(s) filed on <u>05 A</u>	<u>ugust 2003</u> .					
2a)⊠	This action is <b>FINAL</b> . 2b) Thi	s action is non-final.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)🖾	Claim(s) 1,6 and 7 is/are pending in the application	ation.					
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)□	Claim(s) is/are allowed.						
6)⊠	Claim(s) <u>1,6 and 7</u> is/are rejected.						
7)	Claim(s) is/are objected to.		<b>,</b>				
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers							
9)[	The specification is objected to by the Examiner	•					
10) 🔲 -	The drawing(s) filed on is/are: a) accep	ted or b)⊡ objected to by the Exa	miner.				
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. S	ee 37 CFR 1.85(a).				
11) 🔲 -	The proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)⊠ All b)□ Some * c)□ None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice 2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	r (PTO-413) Paper No(s). <u>21</u> . Patent Application (PTO-152) lignment .				

Application/Control Number: 09/700,770 Page 2

Art Unit: 1642

## **DETAILED ACTION**

1. The amendment filed 8/5/2003 (paper no. 19) is acknowledged and entered into the record. Accordingly, claims 2,3,4 and 5 are cancelled without prejudice or disclaimer and claim 7 is newly added.

2. Claims 1, 6 and 7 are therefore pending and examined on the merits.

### **NEW ARGUMENTS**

## Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 4. Claims 1, 6 and 7 are rejected under 35 U.S.C. 102(e) as being anticipated by Bandman *et al* (US Patent 6,203,979). Claims are drawn to a method of detecting the presence of lung cancer in a patient comprising measuring the levels SEQ ID Nos: 2,3,4,5, or 6, and comparing said levels of the polynucleotide of patient with that of a control, wherein an increase is over the control is associated with the presence of lung cancer (claim 1). The claims are further limited to the polynucleotide comprising SEQ ID No: 3 or 6 (claim 6), and the polynucleotide comprising SEQ ID No: 3.

Application/Control Number: 09/700,770

Art Unit: 1642

Bandman *et al* teaches a method of detecting and quantitating a polynucleotide sequence encoding HUPM (see column 6, lines 8-10 and column 33-34), of which is 100% identical to that of SEQ ID No: 3 taught in the instant specification. It is also taught that the detection must be accompanied with a comparison with normalized controls (see column 35, lines 12-14). Furthermore, Bandman *et al* contemplate the use of the method for the detection and diagnosis of cell proliferative disorders of the lung (see column 34, lines 25-40).

All other rejections are withdrawn in view of the applicant's amendments and arguments thereto as set forth in Paper No. 13.

#### Conclusion

- 6. No claim is allowed.
- 7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Application/Control Number: 09/700,770 Page 4

Art Unit: 1642

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Christopher Yaen Art Unit 1642 October 16, 2003

